Of critical importance for evaluating the potential clinical value of the treatments assessed here, the relative expressions of IL-1β, TNF-α, IL-6, and INF-γ in MS patients taking fingolimod (the MSW group) were substantially lower than those of patients taking other medications (the MSO group). Here, IL1B is linked to myeloid sarcoma.